New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareRetatrutide vs Sermorelin

Retatrutide vs Sermorelin

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Retatrutide
Growth Hormone PeptidesAnti-Aging & Longevity
Sermorelin
Summary
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
Half-Life
~10–12 days
10–20 minutes
Admin Route
SubQ
SubQ
Research
Typical Dose
0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
200–500 mcg
Frequency
Once weekly
5–7 days per week
Key Benefits
  • ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
  • Superior to both semaglutide and tirzepatide in early trial comparisons
  • Triple receptor mechanism addresses multiple obesity pathways
  • Significant reduction in liver fat (MASH/NAFLD indication being studied)
  • Improved cardiovascular and metabolic markers
  • Once-weekly dosing
  • Potential for greatest weight loss of any currently investigated compound
  • Increases energy and vitality
  • Improves body composition (more muscle, less fat)
  • Enhances skin thickness and elasticity
  • Strengthens immune system
  • Improves sleep quality and REM sleep
  • Supports bone density
  • Enhances mental clarity and focus
  • Safer than exogenous HGH — respects natural feedback loops
  • FDA-approved for GH diagnostic use
Side Effects
  • Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
  • Diarrhea
  • Constipation
  • Heart rate increase (from glucagon receptor agonism)
  • +2 more
  • Injection site irritation
  • Flushing
  • Headache
  • Dizziness
  • +2 more
Stacks With